Update your location to show providers, locations, and services closest to you.
Endocrinologist (Diabetes & Hormones Specialist)
Dr. Cusi is the principal investigator of a number of ongoing clinical research projects. His grants focus on cutting-edge research in adult endocrinology, diabetes and metabolism, both on clinical and basic research aspects related to the role of obesity and lipotoxicity in the development of Type 2 diabetes and its complications, in particular, the pathogenesis of NAFLD. He has published more than 90 original articles, invited reviews and book chapters in the main journals in the fields of obesity, diabetes and liver disease. Dr. Cusi is a nationally and internationally recognized investigator and speaker on the impact of NAFLD in humans,. His observation in 2006 (NEJM, 2006) that pioglitazone is an effective pharmacological treatment for NASH in people with prediabetes or T2D, confirmed in a 3-year study (Annals Intern Med, 2016), has been incorporated into all major NAFLD guidelines for the management of NAFLD. His current work centers on discovering underlying mechanisms of NAFLD and new treatments. He is an advocate for liver screening in type 2 diabetes and other groups at high-risk groups of cirrhosis from NASH. Most recently involved in the multidisciplinary 2021 AGA consensus statement, 2021 ALEH NAFLD guidance, 2022 AACE NAFLD clinical practice guideline, and 2023 ADA Standards of Care related to NAFLD.
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific…
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part…
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
218 publications
2024
Hepatology
Publisher's site2024
Annals of hepatology
PubMed • Publisher's site2024
Journal of hepatology
PubMed • Publisher's site2024
Hepatology
Publisher's site2024
Journal of Hepatology
Publisher's site